






Supplementary figure 1























































































































Supplementary figure 2








MR effect size for
'TD CD4+ AC' on 'Cholangitis (primary sclerosing, PSC), with reimbursement 202 || id:finn-b-K11_CHOLANGI_S




MR effect size for
'CD20 on IgD+ CD38- naive' on 'Cholangitis (primary sclerosing, PSC), with reimbursement 202 || id:finn-b-K11_CHOLA










MR effect size for
'CD39+ resting Treg % CD4 Treg' on 'Cholangitis (primary sclerosing, PSC), with reimbursement 202 || id:finn-b-K11_CHO







MR effect size for
'DN (CD4-CD8-) NKT %lymphocyte' on 'Cholangitis (primary sclerosing, PSC), with reimbursement 202 || id:finn-b-K11_CH'






MR effect size for
'DN (CD4-CD8-) NKT %T cell' on 'Cholangitis (primary sclerosing, PSC), with reimbursement 202 || id:finn-b-K11_CHOL'








MR effect size for
'CD25 on CD39+ CD4+' on 'Cholangitis (primary sclerosing, PSC), with reimbursement 202 || id:finn-b-K11_CHOLAN





MR effect size for
'HLA DR on HLA DR+ CD8br' on 'Cholangitis (primary sclerosing, PSC), with reimbursement 202 || id:finn-b-K11_CHOLA


















MR effect size for
'CD4 on CD4 Treg' on 'Cholangitis (primary sclerosing, PSC), with reimbursement 202 || id:finn-b-K11_CHOLANGI














MR effect size for
'HLA DR on CD33dim HLA DR+ CD11b-' on 'Cholangitis (primary sclerosing, PSC), with reimbursement 202 || id:finn-b-K11_C











MR effect size for
'CD3 on CD39+ secreting Treg' on 'Cholangitis (primary sclerosing, PSC), with reimbursement 202 || id:finn-b-K11_CHOL

